Nathaniel A. Brown
Corporate Officer/Principal chez Presidio Pharmaceuticals, Inc.
Profil
Nathaniel A.
Brown is currently the Chief Medical Adviser at Presidio Pharmaceuticals, Inc. He previously worked as the Director-Clinical & Scientific Affairs at Glaxo Wellcome, Inc. and as the Chief Medical Officer & Executive Vice President at Idenix Pharmaceuticals LLC.
Dr. Brown completed his undergraduate degree at Yale University and his doctorate degree at Georgetown University.
Postes actifs de Nathaniel A. Brown
| Sociétés | Poste | Début |
|---|---|---|
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - |
Anciens postes connus de Nathaniel A. Brown
| Sociétés | Poste | Fin |
|---|---|---|
| IDENIX PHARMACEUTICALS INC | Directeur Technique/Scientifique/R&D | 17/01/2007 |
| Glaxo Wellcome, Inc. | Directeur Technique/Scientifique/R&D | - |
Formation de Nathaniel A. Brown
| Yale University | Undergraduate Degree |
| Georgetown University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Presidio Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Health Technology |
| Glaxo Wellcome, Inc. | Health Technology |
